BLU — BELLUS Health Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- $1.87bn
- $1.56bn
- $0.02m
Brief: BELLUS Health Reports Launch of Public Offering of Common Shares in Canada, U.S.
Brief: Bellus Health Announces Positive End-Of-Phase 2 Meeting With FDA And Its CALM Phase 3 Program For Blu-5937 In Refractory Chronic Cough
Brief: BELLUS Health Reports Q1 2022 Results And Business Highlights
Brief: Bellus Health To Present Late-Breaking Clinical Data From The Phase 2B Soothe Trial Of Blu-5937
Brief: BELLUS Health Ended Year With Cash, Cash Equivalents And Short-Term Investments Totaling $248.8 Million
Brief: Bellus Health Announces Pricing Of Us$200 Million Public Offering In Canada And The United States
Bellus Health launches $175 mln equity offering after shares soar
Brief: Bellus Health Says Amending And Restating Short Form Base Shelf Prospectus Dated December 23, 2020
Brief: BELLUS Health Launches Share Offering In Canada And United States
U.S. STOCKS ON THE MOVE-Novavax, Harley-Davidson, Peloton, Arena Pharma
Bellus Health soars as cough therapy succeeds in study
Brief: Bellus Health Announces Positive Topline Results From Its Phase 2B Soothe Trial Of Blu-5937 For Treatment Of Refractory Chronic Cough
Brief: Bellus Health Posts Q3 Loss Per Share Of 29 Cents
Brief: Bellus Health Completes Patient Enrollment In SOOTHE Phase 2b Trial For Refractory Chronic Cough
Brief: Bellus Health Announces Positive Interim Analysis From Phase 2B SOOTHE Trial Of BLU-5937 In Refractory Chronic Cough
Brief: Bellus Health To Report Additional Relief Data In An Oral Presentation At The European Respiratory Society International Congress 2021
Brief: Bellus Health Inc Posts Q2 Loss Per Share $0.23
Brief: Bellus Health Posts Quarterly Loss Per Share Of $0.20
Brief: BELLUS Health Reports Year 2020 Financial Results